Woodcock: COVID-19 Pandemic Is Not The Time For Structural Changes At US FDA
Executive Summary
Acting FDA Commissioner Janet Woodcock says FDA is interested in establishing new ‘Centers of Excellence’ but the current environment is not the right time to make changes at the agency. Woodcock also talked about where FDA will spend its new pandemic money and its reexamination of accelerated approval drugs in a wide-sweeping conversation with the Alliance for a Stronger FDA.
You may also be interested in...
Accelerated Approval: US FDA Panel To Reconsider Six Indications For Checkpoint Inhibitors
Oncologic Drugs Advisory Committee will meet for three days in April to consider whether indications for Tecentriq, Keytruda and Opdivo should remain on label despite failure to confirm clinical benefit; review is part of the Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals, which has led to withdrawals of four other PD-1/L-1 inhibitor claims.
US FDA COVID Funds Move Forward In Congress, No Strings Attached
Amendment to require one-firth of the money be devoted to therapeutic review was defeated by the House Energy and Commerce Committee.
A Visual Guide To How FDA Can Manage The Pandemic
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.